Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy - Archive ouverte HAL Access content directly
Journal Articles JNCI: Journal of the National Cancer Institute Year : 2021

Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy

(1) , (1) , (1) , (1) , (1) , (1) , (1) , (2) , (3) , (4) , (5) , (6) , (1) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (1) , (3) , (16) , (17) , (17) , (17) , (18) , (19) , (2) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Pataje Prasanna
Deborah Citrin
Guangrong Zheng
Jorg Goronzy
Stephen Kron
Norman Sharpless
Judith Campisi
Francois Paris
David Gewirtz
Mohamed Abazeed
James Kirkland
Ann Richmond
Marc Mendonca

Abstract

Abstract Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of “one-two punch” cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.
Fichier principal
Vignette du fichier
djab064.pdf (1.81 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03547029 , version 1 (28-01-2022)

Identifiers

Cite

Pataje Prasanna, Deborah Citrin, Jeffrey Hildesheim, Mansoor Ahmed, Sundar Venkatachalam, et al.. Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. JNCI: Journal of the National Cancer Institute, 2021, 113 (10), pp.1285-1298. ⟨10.1093/jnci/djab064⟩. ⟨inserm-03547029⟩
15 View
21 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More